Mandate

Vinge advises Vostok New Ventures Ltd

February 25, 2019 Capital Markets and Public M&A

Vinge has advised Vostok New Ventures Ltd with capital markets related questions in light of the company’s divestment of its portfolio asset Avito, for in total USD 540 million, equivalent of approximately SEK 4,842 million, as well as in connection with the subsequent split and mandatory redemption program whereby each depository receipt holder (“SDRs”) will receive a cash consideration of SEK 25 per SDR.

In total, the company will redeem approximately 81,000,000 SDRs for a cash consideration amount of approximately SEK 2 billion. 

The redemption procedure was approved by a special general meeting in Vostok New Ventures on 14 February 2019. The redemption SDRs will be traded on Nasdaq Stockholm during the period 22 February – 7 March 2019.

Vinge’s team primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Annika Nyberg Ekenberg, Henrik Wastenson and Emelie Svanberg.
 

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026